Biomea Fusion - BMEA Total Company Value-to-Revenue Ratio

Public company logo of biomeafusion.com (BMEA)

The EV/Sales valuation chart demonstrates market expectations for Biomea Fusion, Inc. (BMEA), where the 0.00 metric indicates the business value status. This price action is driven by the utilization of the FUSION system to combat metabolic dysfunction. Risks are mitigated by the development of covalent drugs targeting oncology and diabetes. Efficiency is maintained through external testing while retaining intellectual property rights.

BMEA Biomea Fusion, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Biomea Fusion Corp - analytical breakdowns and key metrics (BMEA)

Initial company analysis:BMEA, biomeafusion.com
Flagship merchandise of Biomea

This metric determines the market value of the business, excluding the impact of debt load on total capitalization. An analysis of the enterprise value-to-revenue ratio allows for tracking the efficiency of sales generation relative to the asset price. The metric compares the total enterprise value with the volume of services rendered. For Biomea Fusion, Inc. (BMEA), this is critical, as lifelong therapy for metabolic disorders ensures a stable revenue stream. The high margins of such products make this indicator key to assessing the fundamental stability of the company.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)